Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 3

2(33.3%)

6Total

Phase 1(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02013362Phase 1Completed

Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Role: lead

NCT01776411Phase 1Completed

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

Role: lead

NCT00823355Phase 1Completed

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Role: lead

NCT01170052Phase 1Withdrawn

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Role: collaborator

NCT00346047Phase 3Completed

Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Low Back Pain

Role: lead

NCT00345787Phase 3Completed

Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain

Role: lead

All 6 trials loaded